Advocacy at a Glance STEVEN GROSSMAN 6/16/23 Advocacy at a Glance STEVEN GROSSMAN 6/16/23 House Appropriations Committee Advances FY 24 Ag/FDA Bill - Senate Markup Set for Thursday, June 22 Read More Analysis and Commentary STEVEN GROSSMAN 6/16/23 Analysis and Commentary STEVEN GROSSMAN 6/16/23 Q&A on House Appropriations Markup Read More Advocacy at a Glance STEVEN GROSSMAN 6/9/23 Advocacy at a Glance STEVEN GROSSMAN 6/9/23 Discretionary Spending Caps in the Fiscal Responsibility Act of 2023 Read More Analysis and Commentary STEVEN GROSSMAN 6/9/23 Analysis and Commentary STEVEN GROSSMAN 6/9/23 Budget Deal Sets Parameters But Many Unknowns Read More Analysis and Commentary STEVEN GROSSMAN 6/2/23 Analysis and Commentary STEVEN GROSSMAN 6/2/23 The Budget Deal - First Impressions from an FDA Perspective Read More Advocacy at a Glance STEVEN GROSSMAN 6/2/23 Advocacy at a Glance STEVEN GROSSMAN 6/2/23 Broad Outlines of the Budget Deal Read More Advocacy at a Glance STEVEN GROSSMAN 5/19/23 Advocacy at a Glance STEVEN GROSSMAN 5/19/23 Alliance Reaction to House Subcommittee Markup Read More Analysis and Commentary STEVEN GROSSMAN 5/19/23 Analysis and Commentary STEVEN GROSSMAN 5/19/23 The Macro- and Micro- Budget Processes and Their Impact on FDA Resources Read More Advocacy at a Glance STEVEN GROSSMAN 5/12/23 Advocacy at a Glance STEVEN GROSSMAN 5/12/23 The Alliance Welcomes New Members Read More Analysis and Commentary STEVEN GROSSMAN 5/12/23 Analysis and Commentary STEVEN GROSSMAN 5/12/23 FDA and the Iron Triangle of Deficit Reduction Read More Analysis and Commentary STEVEN GROSSMAN 5/5/23 Analysis and Commentary STEVEN GROSSMAN 5/5/23 Hill Days and the Bumpy FY 24 Appropriations Cycle Read More Advocacy at a Glance STEVEN GROSSMAN 5/5/23 Advocacy at a Glance STEVEN GROSSMAN 5/5/23 Alliance Completes Second Round of Hill Days with Senate Focus Read More Analysis and Commentary STEVEN GROSSMAN 4/28/23 Analysis and Commentary STEVEN GROSSMAN 4/28/23 Top Ten Challenges Facing FDA Read More Advocacy at a Glance STEVEN GROSSMAN 4/28/23 Advocacy at a Glance STEVEN GROSSMAN 4/28/23 Hill Days: House Completed, Senate Up Next! Read More Analysis and Commentary STEVEN GROSSMAN 4/21/23 Analysis and Commentary STEVEN GROSSMAN 4/21/23 Q&A About FDA and the FY 24 Budget/Appropriations Process Read More Advocacy at a Glance STEVEN GROSSMAN 4/21/23 Advocacy at a Glance STEVEN GROSSMAN 4/21/23 We are Excited for Our Upcoming Alliance Hill Days. Please Participate! Read More Analysis and Commentary STEVEN GROSSMAN 4/14/23 Analysis and Commentary STEVEN GROSSMAN 4/14/23 Alliance Testifies to the House and Senate on FY 24 Appropriations Read More Advocacy at a Glance STEVEN GROSSMAN 4/14/23 Advocacy at a Glance STEVEN GROSSMAN 4/14/23 Alliance Hill Days Are Coming Up. Please Participate! Read More Advocacy at a Glance STEVEN GROSSMAN 4/6/23 Advocacy at a Glance STEVEN GROSSMAN 4/6/23 Alliance Hill Days Scheduled for April 25 and 26. Please Participate! Read More Analysis and Commentary STEVEN GROSSMAN 4/6/23 Analysis and Commentary STEVEN GROSSMAN 4/6/23 FDA’s FY 24 Budget Q&A Read More Newer Posts Older Posts
Advocacy at a Glance STEVEN GROSSMAN 6/16/23 Advocacy at a Glance STEVEN GROSSMAN 6/16/23 House Appropriations Committee Advances FY 24 Ag/FDA Bill - Senate Markup Set for Thursday, June 22 Read More
Analysis and Commentary STEVEN GROSSMAN 6/16/23 Analysis and Commentary STEVEN GROSSMAN 6/16/23 Q&A on House Appropriations Markup Read More
Advocacy at a Glance STEVEN GROSSMAN 6/9/23 Advocacy at a Glance STEVEN GROSSMAN 6/9/23 Discretionary Spending Caps in the Fiscal Responsibility Act of 2023 Read More
Analysis and Commentary STEVEN GROSSMAN 6/9/23 Analysis and Commentary STEVEN GROSSMAN 6/9/23 Budget Deal Sets Parameters But Many Unknowns Read More
Analysis and Commentary STEVEN GROSSMAN 6/2/23 Analysis and Commentary STEVEN GROSSMAN 6/2/23 The Budget Deal - First Impressions from an FDA Perspective Read More
Advocacy at a Glance STEVEN GROSSMAN 6/2/23 Advocacy at a Glance STEVEN GROSSMAN 6/2/23 Broad Outlines of the Budget Deal Read More
Advocacy at a Glance STEVEN GROSSMAN 5/19/23 Advocacy at a Glance STEVEN GROSSMAN 5/19/23 Alliance Reaction to House Subcommittee Markup Read More
Analysis and Commentary STEVEN GROSSMAN 5/19/23 Analysis and Commentary STEVEN GROSSMAN 5/19/23 The Macro- and Micro- Budget Processes and Their Impact on FDA Resources Read More
Advocacy at a Glance STEVEN GROSSMAN 5/12/23 Advocacy at a Glance STEVEN GROSSMAN 5/12/23 The Alliance Welcomes New Members Read More
Analysis and Commentary STEVEN GROSSMAN 5/12/23 Analysis and Commentary STEVEN GROSSMAN 5/12/23 FDA and the Iron Triangle of Deficit Reduction Read More
Analysis and Commentary STEVEN GROSSMAN 5/5/23 Analysis and Commentary STEVEN GROSSMAN 5/5/23 Hill Days and the Bumpy FY 24 Appropriations Cycle Read More
Advocacy at a Glance STEVEN GROSSMAN 5/5/23 Advocacy at a Glance STEVEN GROSSMAN 5/5/23 Alliance Completes Second Round of Hill Days with Senate Focus Read More
Analysis and Commentary STEVEN GROSSMAN 4/28/23 Analysis and Commentary STEVEN GROSSMAN 4/28/23 Top Ten Challenges Facing FDA Read More
Advocacy at a Glance STEVEN GROSSMAN 4/28/23 Advocacy at a Glance STEVEN GROSSMAN 4/28/23 Hill Days: House Completed, Senate Up Next! Read More
Analysis and Commentary STEVEN GROSSMAN 4/21/23 Analysis and Commentary STEVEN GROSSMAN 4/21/23 Q&A About FDA and the FY 24 Budget/Appropriations Process Read More
Advocacy at a Glance STEVEN GROSSMAN 4/21/23 Advocacy at a Glance STEVEN GROSSMAN 4/21/23 We are Excited for Our Upcoming Alliance Hill Days. Please Participate! Read More
Analysis and Commentary STEVEN GROSSMAN 4/14/23 Analysis and Commentary STEVEN GROSSMAN 4/14/23 Alliance Testifies to the House and Senate on FY 24 Appropriations Read More
Advocacy at a Glance STEVEN GROSSMAN 4/14/23 Advocacy at a Glance STEVEN GROSSMAN 4/14/23 Alliance Hill Days Are Coming Up. Please Participate! Read More
Advocacy at a Glance STEVEN GROSSMAN 4/6/23 Advocacy at a Glance STEVEN GROSSMAN 4/6/23 Alliance Hill Days Scheduled for April 25 and 26. Please Participate! Read More
Analysis and Commentary STEVEN GROSSMAN 4/6/23 Analysis and Commentary STEVEN GROSSMAN 4/6/23 FDA’s FY 24 Budget Q&A Read More
